BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//UCLA - ECPv5.14.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UCLA
X-ORIGINAL-URL:https://www.chemistry.ucla.edu
X-WR-CALDESC:Events for UCLA
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20210121T160000
DTEND;TZID=America/Los_Angeles:20210121T160000
DTSTAMP:20260618T194222
CREATED:20210107T005013Z
LAST-MODIFIED:20210107T005013Z
UID:13414-1611244800-1611244800@www.chemistry.ucla.edu
SUMMARY:Novel GABA- and Ornithine Aminotransferase Inactivators and Potential New Treatments for Epilepsy\, Addiction\, Neuropathic Pain\, and Hepatocellular Carcinoma
DESCRIPTION:Abstract: An imbalance in the levels of the inhibitory neurotransmitter g-aminobutyric acid (GABA) and the excitatory neurotransmitter L-glutamate can lead to convulsions. Inhibition of g-aminobutyric acid aminotransferase (GABA-AT)\, the enzyme responsible for the degradation of GABA\, increases brain GABA levels\, which has been shown to produce an anticonvulsant effect. Reduced brain GABA concentration also is a feature of neuropathic pain. A sharp rise in dopamine release is associated with a variety of addictive behaviors. This dopamine release can be attenuated by an increase in GABA; therefore\, inactivation of GABA-AT also has an effect on addictive behavior. Inactivation of a related enzyme\, ornithine aminotransferase (OAT) in hepatocellular carcinoma (HCC) has been shown to slow the growth of this cancer. In this lecture the design and mechanism of some of our GABA-AT inactivators will be discussed and how these compounds led to the design and discovery of CPP-115 and OV329\, potent inactivators of GABA-AT\, which have been found to have excellent pharmacokinetic and pharmacological properties for the potential treatment of epilepsy\, neuropathic pain\, and addiction. An analog related to CPP-115 was identified that does not inactivate GABA-AT but is a potent inactivator of OAT. Enzyme inactivator design and mechanism studies will be discussed\, as well as in vitro and in vivo efficacy and pharmacokinetic results\, toxicology studies\, and a clinical trial with CPP-115.
URL:https://www.chemistry.ucla.edu/seminars/novel-gaba-and-ornithine-aminotransferase-inactivators-and-potential-new-treatments/
CATEGORIES:Organic Colloquium,Seminars
END:VEVENT
END:VCALENDAR